Afficher la notice abrégée

dc.contributor.authorGonçalves, Jaime
dc.contributor.authorSancho Sánchez, Consuelo 
dc.contributor.authorLópez, Dolores E.
dc.contributor.authorCastellano Benítez, Orlando 
dc.contributor.authorGarcía Cenador, María Begoña 
dc.contributor.authorServilha Menezes, Gabriel
dc.contributor.authorCorchado Rodríguez, Juan Manuel 
dc.contributor.authorGarcía Cairasco, Norberto
dc.contributor.authorGonçalves Estella, Jesús María 
dc.date.accessioned2025-01-15T17:31:32Z
dc.date.available2025-01-15T17:31:32Z
dc.date.issued2023
dc.identifier.citationGonçalves-Sánchez, J.; Sancho, C.; López, D.E.; Castellano, O.; García-Cenador, B.; Servilha-Menezes, G.; Corchado, J.M.; García-Cairasco, N.; Gonçalves-Estella, J.M. Effect of Vagus Nerve Stimulation on the GASH/Sal Audiogenic-Seizure-Prone Hamster. Int. J. Mol. Sci. 2024, 25, 91. https:// doi.org/10.3390/ijms25010091es_ES
dc.identifier.urihttp://hdl.handle.net/10366/161829
dc.description.abstract[ES] El hamster epiléptico "GASH/Sal" (Genetic Audiogenic Seizures Hamster / Salamanca) es el resultado de una mutación espontánea natural y constituye un modelo animal ideal de epilepsia refleja, ya que ante un sonido de unos determinados parámetros responde siempre con crisis. Decidimos profundizar en el conocimiento de la estimulación del nervio vago en este modelo. Nuestro trabajo demuestra la efectividad de la terapia crónica o a largo plazo mediante el empleo de dispositivos plenamente implantables, probando los dispositivos comerciales existentes y con el desarrollo de un generador adecuado al tamaño del hamster. El mecanismo de acción está mediado por el descenso de mediadores inflamatorios.es_ES
dc.description.abstract[EN] Vagus nerve stimulation (VNS) is an adjuvant neuromodulation therapy for the treatment of refractory epilepsy. However, the mechanisms behind its effectiveness are not fully understood. Our aim was to develop a VNS protocol for the Genetic Audiogenic Seizure Hamster from Salamanca (GASH/Sal) in order to evaluate the mechanisms of action of the therapy. The rodents were subject to VNS for 14 days using clinical stimulation parameters by implanting a clinically available neurostimulation device or our own prototype for laboratory animals. The neuroethological assessment of seizures and general behavior were performed before surgery, and after 7, 10, and 14 days of VNS. Moreover, potential side effects were examined. Finally, the expression of 23 inflammatory markers in plasma and the left-brain hemisphere was evaluated. VNS significantly reduced seizure severity in GASH/Sal without side effects. No differences were observed between the neurostimulation devices. GASH/Sal treated with VNS showed statistically significant reduced levels of interleukin IL-1β, monocyte chemoattractant protein MCP-1, matrix metalloproteinases (MMP-2, MMP-3), and tumor necrosis factor TNF-α in the brain. The described experimental design allows for the study of VNS effects and mechanisms of action using an implantable device. This was achieved in a model of convulsive seizures in which VNS is effective and shows an anti-inflammatory effect.en
dc.language.isoenges_ES
dc.publisherHenry Hing Cheong Lee, Julija Veljković & Mauricio Battinoes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectanimal models of epilepsyes_ES
dc.subjectaudiogenic epilepsyes_ES
dc.subjectexperimental surgeryes_ES
dc.subjectvagus nerve stimulationes_ES
dc.subject.meshEpilepsy, Reflex *
dc.subject.meshVagus Nerve Stimulation *
dc.subject.meshAnimals *
dc.subject.meshCricetinae *
dc.subject.meshSeizures *
dc.titleEffect of Vagus Nerve Stimulation on the GASH/Sal Audiogenic-Seizure-Prone Hamsteres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.subject.unesco2490 Neurocienciases_ES
dc.subject.unesco3213.08 Neurocirugíaes_ES
dc.subject.unesco3213.06 Cirugía Experimentales_ES
dc.identifier.doi10.3390/ijms25010091
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/824164/EUes_ES
dc.relation.projectIDGerencia Regional de Salud de Castilla y Leon 1600/A/17es_ES
dc.relation.projectIDGerencia Regional de Salud de Castilla y Leon 1838/A/18es_ES
dc.relation.projectIDGerencia Regional de Salud de Castilla y Leon 2060/A/19es_ES
dc.relation.projectIDGerencia Regional de Salud de Castilla y Leon 2158/A/20es_ES
dc.relation.projectIDGerencia Regional de Salud de Castilla y Leon 2382/A/21es_ES
dc.relation.projectIDFundacao de Amparo a Pesquisa do Estado de Sao Paulo in Brazil (USAL/FAPESP SPRINT-Sao Paulo Researchers inInternational Collaboration) 2019/16574-2es_ES
dc.relation.projectIDSpanish Government FPU 18/04070es_ES
dc.relation.projectIDCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) 001es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn1422-0067
dc.journal.titleInternational Journal of Molecular Scienceses_ES
dc.volume.number25es_ES
dc.issue.number91es_ES
dc.page.initial1es_ES
dc.page.final20es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsestimulación del nervio vago *
dc.subject.decsanimales *
dc.subject.decsconvulsiones *
dc.subject.decsCricetinae *
dc.subject.decsepilepsia refleja *


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional